AZD6793 for COPD
(PRESTO Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new drug, AZD6793, to evaluate its effectiveness and safety for people with chronic obstructive pulmonary disease (COPD). Researchers aim to determine the best dose among three options by comparing them to a placebo (a pill with no active medicine). This trial suits individuals who have had moderate to very severe COPD for at least a year, experience frequent flare-ups, and are already on a stable inhaler routine. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group, providing an opportunity to contribute to significant advancements in COPD treatment.
Do I need to stop my current medications for the trial?
The trial does not specify if you need to stop your current medications, but it requires a stable regimen of inhaled maintenance therapy for at least 3 months before screening.
Is there any evidence suggesting that AZD6793 is likely to be safe for humans?
Research has shown that AZD6793 underwent safety testing in earlier studies. These studies assessed how well participants tolerated the drug in single doses. Results indicated that AZD6793 was generally well-tolerated, with no major safety concerns reported. This treatment targets chronic obstructive pulmonary disease (COPD) by blocking specific pathways involved in the disease. While earlier tests suggest safety, the current trial aims to gather more detailed information. Specifically, the researchers are evaluating the safety and effectiveness of different doses.12345
Why do researchers think this study treatment might be promising for COPD?
Researchers are excited about AZD6793 for COPD because it potentially offers a new approach compared to standard treatments like bronchodilators and corticosteroids. While most current therapies aim to open airways and reduce inflammation, AZD6793 might work by specifically targeting new pathways involved in the disease's progression. This innovative mechanism could lead to better control of symptoms and possibly slow disease progression. If successful, AZD6793 could provide a much-needed alternative for patients who do not respond well to existing treatments.
What evidence suggests that AZD6793 might be an effective treatment for COPD?
Research suggests that AZD6793 might help people with COPD (chronic obstructive pulmonary disease) by improving lung function. Studies have found that AZD6793 targets specific body parts to reduce inflammation, a major issue in COPD. In early animal tests, the drug reduced symptoms like shortness of breath and coughing. Although detailed information from human studies remains limited, early trials showed the drug is generally safe and doesn't cause serious side effects. Researchers continue to investigate these benefits, but initial results are promising for those with moderate to very severe COPD.12356
Who Is on the Research Team?
Dave Singh, MD
Principal Investigator
Medicines Evaluation Unit, Manchester University NHS Foundations Trust, Manchester, United Kingdom
Are You a Good Fit for This Trial?
This trial is for people with moderate to very severe chronic obstructive pulmonary disease (COPD). Specific eligibility criteria are not provided, but typically participants must meet certain health conditions and agree to the study's procedures.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive one of three doses of AZD6793 or placebo for 24 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AZD6793
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology